<DOC>
	<DOC>NCT02770261</DOC>
	<brief_summary>The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.</brief_summary>
	<brief_title>Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Both man and woman who is over 19years old. Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP is under 180mmHg and Mean msDBP is under 110mmHg and LDLC is 250mg/DL or under and Triglycerides is under 400mg/dL Therapeutic lifestylechange is not enought during the study period SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at screening visit</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>DP-R208</keyword>
</DOC>